Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals

Bibliography

• Preskorn SH. The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol. J Psychiatr Pract 2007;13:253-7
   PubMedGoogle Scholar
• Feltus MS, Gardner DM. Second generation antipsychotics for schizophrenia. Can J Clin Pharmacol 1999;6:187-95
   PubMedGoogle Scholar
• Bottlender R, Strauss A, Moller HJ. Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. Schizophr Res 2010;116:9-15
   PubMed Web of Science ®Google Scholar
• Marwaha S, Johnson S. Schizophrenia and employment - a review. Soc Psychiatry Psychiatr Epidemiol 2004;39:337-49
   PubMed Web of Science ®Google Scholar
• D'Amore J, Hung O, Chiang W, The epidemiology of the homeless population and its impact on an urban emergency department. Acad Emerg Med 2001;8:1051-5
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd edition. American Psychiatric Association; Arlington, VA: 2004
   Google Scholar
• Montes JM, Ciudad A, Gascon J, Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:667-74
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Amoretti A, Forghieri M, Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol 2007;15:569-75
   PubMed Web of Science ®Google Scholar
• Ratner Y, Gibel A, Yorkov V, Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1401-9
   PubMed Web of Science ®Google Scholar
• Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003;64:451-8
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Gopa S. Comparative study of risperidone and haloperidol on clinical and psychosocial parameters in treatment of schizophrenia: a randomized open trial. Indian J Psychiatry 2000;42:52-6
   PubMedGoogle Scholar
• Poyurovsky M, Koren D, Gonopolsky I, Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 2003;13:123-8
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11:59-67
   PubMed Web of Science ®Google Scholar
• Saleem P, Olie JP, Loo H. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 2002;17:1-8
   PubMed Web of Science ®Google Scholar
• Tyson PJ, Laws KR, Flowers KA, Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry Clin Neurosci 2006;60:473-9
   PubMed Web of Science ®Google Scholar
• Swartz MS, Perkins DO, Stroup TS, Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-36
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-6
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-83
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-84
   PubMed Web of Science ®Google Scholar
• Mauri MC, Volonteri LS, Colasanti A, Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88
   PubMed Web of Science ®Google Scholar
• Uchida H, Takeuchi H, Graff-Guerrero A, Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 2011;31:318-25
   PubMed Web of Science ®Google Scholar
• Rainer MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008;4:919-27
   PubMedGoogle Scholar
• Dlugosz H, Nasrallah HA. Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin Pharmacother 2007;8:2307-13
   PubMed Web of Science ®Google Scholar
• Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs 2010;24:227-44
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009;63:140-50
   PubMed Web of Science ®Google Scholar
• Baldwin CM, Scott LJ. Quetiapine extended release: in schizophrenia. CNS Drugs 2009;23:261-9
   PubMed Web of Science ®Google Scholar
• Schotte A, Bonaventure P, Janssen PF, In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995;69:399-412
   PubMedGoogle Scholar
• Leysen JE, Janssen PM, Schotte A, Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):40-54
   Web of Science ®Google Scholar
• Abbas AI, Hedlund PB, Huang XP, Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009;205:119-28
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005;27:289-304
   PubMed Web of Science ®Google Scholar
• Seeman P. Update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005;162:1984-5
   PubMed Web of Science ®Google Scholar
• McCreary AC, Jones CA. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism. Curr Pharm Des 2010;16:516-21
   PubMed Web of Science ®Google Scholar
• Coyle JT, Balu D, Benneyworth M, Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci 2010;12:359-82
   PubMedGoogle Scholar
• Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit 2005;27:103-6
   PubMed Web of Science ®Google Scholar
• Bai YM, Ting Chen T, Chen JY, Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:1218-25
   PubMed Web of Science ®Google Scholar
• Nord M, Nyberg S, Brogren J, Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011;14:1357-66
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005;6:129-37
   PubMedGoogle Scholar
• Karlsson P, Dencker E. Nyberg, S, et al. Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 2005;15:S385
   Web of Science ®Google Scholar
• Mamo D, Kapur S, Keshavan M, D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33:298-304
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Duchesne I, Mehnert A, Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004;65:531-6
   PubMed Web of Science ®Google Scholar
• Moller HJ, Llorca PM, Sacchetti E, Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30
   PubMed Web of Science ®Google Scholar
• Marinis TD, Saleem PT, Glue P, Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007;40:257-63
   PubMed Web of Science ®Google Scholar
• Lloyd K, Latif MA, Simpson S, Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol 2010;25:243-52
   PubMed Web of Science ®Google Scholar
• Schmauss M, Sacchetti E, Kahn JP, Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 2007;22:85-92
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364:842-51
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Keks NA, Ingham M, Khan A, Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burns T, Morosini P, Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. Clin Ther 2010;32:275-92
   PubMed Web of Science ®Google Scholar
• Emsley R, Berwaerts J, Eerdekens M, Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-56
   PubMed Web of Science ®Google Scholar
• Canuso CM, Bossie CA, Amatniek J, Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Early Interv Psychiatry 2010;4:64-78
   PubMed Web of Science ®Google Scholar
• Canuso CM, Turkoz I, Sheehan JJ, Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Disord 2010;120:193-9
   PubMed Web of Science ®Google Scholar
• Canuso CM, Bossie CA, Turkoz I, Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009;113:56-64
   PubMed Web of Science ®Google Scholar
• Schreiner A, Hoeben D, Lahaye M, A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with aripiprazole. Schizophr Res 2010;117:499
   Web of Science ®Google Scholar
• Schreiner A, Hoeben D, Lahaye M, A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone. Eur Psychiatry 2010;25:1107
   Web of Science ®Google Scholar
• Schreiner A, Dilbaz N, Kotler M, Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral olanzapine. Eur Psychiatry 2010;25:110851
   Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie CA, Sliwa JK, Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011;10:12
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2011;25:685-97
   PubMed Web of Science ®Google Scholar
• Sliwa JK, Bossie CA, Ma YW, Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res 2011;132:28-34
   PubMed Web of Science ®Google Scholar
• Gopal S, Pandina G, Lane R, A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci 2011;8:26-33
   PubMedGoogle Scholar
• Pandina G, Lane R, Gopal S, A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1002-8
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane R, A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;22:1-12
   Google Scholar
• Witte MM, Case MG, Schuh KJ, Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin 2012;28:315-23
   PubMed Web of Science ®Google Scholar
• Godfrey JL, Detke HC, Montgomery WS, Quality of life and patient-reported outcomes: comparisons of individuals with schizophrenia treated with oral and long-acting injectable formulations of olanzapine. Value Health 2009;12:17
   Web of Science ®Google Scholar
• Jarbrink K, Kreif N, Benedict A, Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2009;25:709-16
   PubMed Web of Science ®Google Scholar
• Soares CN, Frey BN, Haber E, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. J Clin Psychopharmacol 2010;30:612-15
   PubMed Web of Science ®Google Scholar
• Bell MD, Lysaker PH. Psychiatric symptoms and work performance among persons with severe mental illness. Psychiatr Serv 1995;46:508-10
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30
   PubMed Web of Science ®Google Scholar
• Velligan DI, Alphs L, Lancaster S, Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res 2009;169:97-100
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Mosolov SN, Potapov AV, Ushakov UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Ann Gen Psychiatry 2012;11:1
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008;23:325-31
   PubMed Web of Science ®Google Scholar
• Huang MW, Yang TT, Ten PR, Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clin Pharmacol 2012;12:1
   PubMedGoogle Scholar
• Gharabawi G, Bossie C, Turkoz I, The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis 2007;195:976-82
   PubMed Web of Science ®Google Scholar
• Hough D, Nuamah IF, Lim P, Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis. J Clin Psychopharmacol 2009;29:496-7
   PubMed Web of Science ®Google Scholar
• Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010;11:2301-17
   PubMed Web of Science ®Google Scholar
• Dolder CR, Lacro JP, Leckband S, Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003;23:389-99
   PubMed Web of Science ®Google Scholar
• Louza MR, Elkis H, Ruschel S, Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia. Neuropsychiatr Dis Treat 2011;7:391-8
   PubMed Web of Science ®Google Scholar
• Nicholl D, Nasrallah H, Nuamah I, Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. Curr Med Res Opin 2010;26:1471-84
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006;26:571-8
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhao F, Detke HC, Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry 2011;11:152
   PubMed Web of Science ®Google Scholar
• Lambert M, Schimmelmann BG, Naber D, Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 2009;42:277-83
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Napryeyenko O, Burba B, Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. J Clin Psychopharmacol 2011;31:75-81
   PubMed Web of Science ®Google Scholar
• Lambert M, De Marinis T, Pfeil J, Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010;25:220-9
   PubMed Web of Science ®Google Scholar
• Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007;22:267-75
   PubMed Web of Science ®Google Scholar
• Marchese G, Casu G, Casti P, Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats. Eur J Pharmacol 2009;620:36-41
   PubMed Web of Science ®Google Scholar
• Marchese G, Pittau B, Casu G, A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Eur Psychiatry 2010;25:92-100
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Kryzhanovskaya LA, Zhao F, Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol 2011;6:422-33
   Google Scholar
• Karow A, Czekalla J, Dittmann RW, Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007;68:75-80
   PubMed Web of Science ®Google Scholar
• Lindstrom LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand Suppl 1994;380:74-6
   PubMedGoogle Scholar
• Datto C, Berggren L, Patel JB, Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31:492-502
   PubMed Web of Science ®Google Scholar